Inhibition of interleukin 10 by Rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis

Clinical Cancer Research

Volumn 7, Issue 3, 2001, Pages 709-723

  Alas, S ^a   Emmanouilides, C ^a   Bonavida, B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUDARABINE; INTERLEUKIN 10; PROTEIN BCL 2; RITUXIMAB; VINBLASTINE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; GENE CONTROL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; APOPTOSIS; CELL DIVISION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-10; LYMPHOMA, NON-HODGKIN; MICE; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034894958     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Characterization of a human B lymphocyte-specific antigen
2. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
3. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
4. IDEC-C2B8: Results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
5. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
6. Clinical status and optimal use of Rituximab for B-cell lymphomas
7. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter Phase II study
8. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines
9. Endogenous IL-10 is a protective factor in drug-resistant AIDS-related lymphoma (ARL)
10. Overcoming TNF-α and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-α or drugs: The role of TNF-α mRNA downregulation in tumor cell sensitization
11. L, and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone
12. L, and Mcl-1 expression
13. L are co-regulated by IL-6 in human myeloma cells
14. L
15. C-Myc and Bcl-2 protein expression during the induction of apoptosis and differentiation in TNF-α-treated HL-60 cells
16. Bcl-2 family proteins: Regulators of chemoresistance in cancer
17. IgMs produced by two acquired immune deficiency syndrome lymphoma cell lines: Ig binding specificity and VH-gene putative somatic mutation analysis
18. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection
19. Surface IgM-κ specificity on a Burkitt lymphoma cell in vivo and in derived culture lines
20. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
21. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells
22. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
23. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
24. Pharmacokinetics of cisplatin and its monohydrated complex in humans
25. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy
26. Pharmacokinetics and metabolism of vinca alkaloids
27. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues
28. Criteria for analyzing interactions between biologically active agents
29. Preferential induction of TNF-α and IL-1β and inhibition of IL-10 secretion by human peripheral blood monocytes by synthetic aza-alkyl lysophospholipids
30. Simplified hot start P.C.R.
31. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications
32. Both HPV and carcinogen contribute to the development of resistance to apoptosis during oral carcinogenesis
33. SHIP recruitment attenuates Fc γ RIIB-induced B cell apoptosis
34. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling
35. Inhibitory signaling by B cell Fc γ RIIb
36. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
37. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
38. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody
39. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1
40. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10
41. The Epstein-Barr virus latent membrane protein-1(LMP1) induces interleukin-10 production in Burkitt lymphoma lines
42. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein
43. Interleukin-10 rescues T cells from apoptotic cell death: Association with an upregulation of Bcl-2
44. Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells
45. Pathogenesis of Burkitt lymphoma: Expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts
46. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo
47. 1 phase of the cell cycle
48. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes
49. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation
50. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20
51. The association between CD20 and Src-family tyrosine kinases requires an additional factor
52. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment
53. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment
54. 2+ conductance found constitutively in B lymphocytes
55. Activation of the calcium-permeable cation channel CD20 by α subunits of the Gi protein
56. Activation of a calcium-permeable cation channel CD20 expressed in Balb/c 3T3 cells by insulin-like growth factor-I
57. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors
58. Human B cell interleukin 10
59. Protective effect of cyclosporin A on immune abnormalities observed in the murine acquired immunodeficiency syndrome
60. CD4+ T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS)
61. CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice
62. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
63. Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor
64. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells
65. Activation of the interleukin-10 gene in the human T lymphoma line HuT 78: Identification and characterization of NF-κB binding sites in the regulatory region of the interleukin-10 gene
66. Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence
67. Stress-resistance conferred by high level of bcl-2 α protein in human B lymphoblastoid cell
68. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation
69. Bcl- 2 functions in an antioxidant pathway to prevent apoptosis
70. Bcl-2 inhibition of neural death: Decreased generation of reactive oxygen species
71. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs
72. DNA damage can induce apoptosis in proliferating lymphoid cells via p53- independent mechanisms inhibitable by Bcl-2
73. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production
74. Tumor necrosis factor-α up-regulates Bcl-2 expression and decreases calcium-dependent apoptosis in human B cell lines
75. Coexpression of translocated and normal c-myc oncogenes in hybrids between Daudi and lymphoblastoid cells
76. Activation of a translocated c-myc gene: Role of structural alterations in the upstream region
77. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and Rituximab
78. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma
79. Interleukin-10 in non-Hodgkin's lymphoma
80. Serum interleukin-10 in acquired immunodeficiency syndrome lymphoma patients
81. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines
82. Evidence for platelet-activating factor receptor subtypes on human polymorphonuclear leukocyte membranes
83. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
84. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma